MX354479B - Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. - Google Patents

Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.

Info

Publication number
MX354479B
MX354479B MX2013014933A MX2013014933A MX354479B MX 354479 B MX354479 B MX 354479B MX 2013014933 A MX2013014933 A MX 2013014933A MX 2013014933 A MX2013014933 A MX 2013014933A MX 354479 B MX354479 B MX 354479B
Authority
MX
Mexico
Prior art keywords
antibody
nitrogen mustard
combination therapy
hodgkin
lymphoma
Prior art date
Application number
MX2013014933A
Other languages
English (en)
Spanish (es)
Other versions
MX2013014933A (es
Inventor
Rojkjaer Lisa
Winderlich Mark
Amersdorfer Jutta
Steidl Stefan
Krohn Susanne
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2013014933A publication Critical patent/MX2013014933A/es
Publication of MX354479B publication Critical patent/MX354479B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013014933A 2011-08-16 2012-08-14 Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. MX354479B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US201261654097P 2012-06-01 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number Publication Date
MX2013014933A MX2013014933A (es) 2014-04-16
MX354479B true MX354479B (es) 2018-03-07

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014933A MX354479B (es) 2011-08-16 2012-08-14 Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.

Country Status (24)

Country Link
US (3) US20140255427A1 (https=)
EP (2) EP2744515B1 (https=)
JP (1) JP6184952B2 (https=)
KR (3) KR20140064873A (https=)
CN (1) CN103732252B (https=)
AU (1) AU2012296907B2 (https=)
BR (1) BR112013033919B1 (https=)
CA (2) CA2841875C (https=)
CY (1) CY1125122T1 (https=)
DK (1) DK2744515T3 (https=)
ES (1) ES2909722T3 (https=)
HR (1) HRP20220228T1 (https=)
HU (1) HUE058350T2 (https=)
IL (1) IL230293B (https=)
LT (1) LT2744515T (https=)
MX (1) MX354479B (https=)
PL (1) PL2744515T3 (https=)
PT (1) PT2744515T (https=)
RS (1) RS63238B1 (https=)
RU (1) RU2625222C2 (https=)
SG (1) SG10201606785UA (https=)
SI (1) SI2744515T1 (https=)
SM (1) SMT202200159T1 (https=)
WO (1) WO2013024097A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
FI3916392T3 (fi) * 2016-05-30 2024-06-03 Incyte Corp Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
US12358983B2 (en) * 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
LT3630177T (lt) * 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CA3255552A1 (en) * 2021-12-22 2023-06-29 Incyte Corporation TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US7112324B1 (en) * 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
WO2000067796A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) * 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
US20110135739A1 (en) * 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor

Also Published As

Publication number Publication date
MX2013014933A (es) 2014-04-16
SG10201606785UA (en) 2016-10-28
EP2744515B1 (en) 2022-02-09
ES2909722T3 (es) 2022-05-10
US20240366756A1 (en) 2024-11-07
CY1125122T1 (el) 2024-12-13
HRP20220228T1 (hr) 2022-05-13
SI2744515T1 (sl) 2022-05-31
KR102115203B1 (ko) 2020-05-28
PL2744515T3 (pl) 2022-05-30
KR20140064873A (ko) 2014-05-28
US20200353077A1 (en) 2020-11-12
US20140255427A1 (en) 2014-09-11
KR20200058583A (ko) 2020-05-27
LT2744515T (lt) 2022-04-25
DK2744515T3 (da) 2022-03-28
CA2841875A1 (en) 2013-02-21
JP2014525926A (ja) 2014-10-02
IL230293B (en) 2019-01-31
RU2014103492A (ru) 2015-09-27
NZ617770A (en) 2016-01-29
AU2012296907B2 (en) 2017-01-05
BR112013033919A2 (pt) 2017-12-19
JP6184952B2 (ja) 2017-08-23
CA2841875C (en) 2021-11-02
CN103732252B (zh) 2017-11-10
HUE058350T2 (hu) 2022-07-28
WO2013024097A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
KR20190107749A (ko) 2019-09-20
PT2744515T (pt) 2022-05-19
EP4062936A1 (en) 2022-09-28
RU2625222C2 (ru) 2017-07-12
CN103732252A (zh) 2014-04-16
RS63238B1 (sr) 2022-06-30
BR112013033919B1 (pt) 2022-11-16
EP2744515A1 (en) 2014-06-25
SMT202200159T1 (it) 2022-05-12

Similar Documents

Publication Publication Date Title
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
TN2015000050A1 (en) Methods of treating a tauopathy
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
CA143991S (en) Dual function wine device
CA141065S (en) Dual c clip
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
IN2014KN01160A (https=)
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
GB201208362D0 (en) Fixing system
MX2022006154A (es) Combinaciones y sus usos.
CA141066S (en) Dual c clip
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MY166063A (en) Intravenous antiviral treatments
UY33207A (es) Métodos de preparación de tiazolidinas
UA60147U (ru) Способ лечения больных хроническим некалькулезным холециститом с сопутствующим ожирением
UA50311U (ru) Способ лечения хронического гиперацидного гастродуоденита у детей

Legal Events

Date Code Title Description
FG Grant or registration